glp 1 drugs for sleep apnea glp-1 Insurance companies scrambling to support need for GLP-1 drugs FDA approves Eli Lilly's weight

It is also approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (Ozempic), and in adults with established cardiovascular disease and either obesity or overweight (Wegovy)

Discontinuation rates due to adverse events were 12.2% and 18.2% with retatrutide 9 mg and 12 mg, respectively, compared to 4.0% with placebo

GLP-1RAs attenuate the progression of NASH to hepatocellular carcinoma through enhancement of hepatic metabolic function

2.3% (diabetes) vs

Alogliptin: Monitor renal function periodically.

Sleep Disorders Obstructive sleep apnea (OSA) represents a significant clinical breakthrough for GLP-1 RAs in sleep medicine, culminating in the historic FDA approval of tirzepatide (Zepbound) on December 20, 2024, as the first medication specifically indicated for moderate-to-severe OSA in adults with obesity [154]